| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2013 | US20130041000 Novel azole compound |
| 02/14/2013 | US20130040999 New compounds for alleviation, prevention or treatment of osteoporosis, the preparation thereof and pharmaceutical composition comprising the same |
| 02/14/2013 | US20130040998 Fluorinated hdac inhibitors and uses thereof |
| 02/14/2013 | US20130040997 Novel pyridine carboxylic acid based compound used as a p2x1 and p2x3 receptor antagonist, a production method for the same and a composition comprising the same |
| 02/14/2013 | US20130040996 Composition for treating atherosclerosis and a preparation method thereof |
| 02/14/2013 | US20130040995 Novel compounds |
| 02/14/2013 | US20130040994 Methods of Treatment Using Allosteric Processing Inhibitors for Matrix Metalloproteinases |
| 02/14/2013 | US20130040992 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands |
| 02/14/2013 | US20130040991 Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide |
| 02/14/2013 | US20130040990 SYNTHESIS OF DGJNAc FROM D-GLUCURONOLACTONE AND USE TO INHIBIT ALPHA-N-ACETYLGALACTOSAMINIDASES |
| 02/14/2013 | US20130040989 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts |
| 02/14/2013 | US20130040988 3-amino-pyridine derivatives for the treatment of metabolic disorders |
| 02/14/2013 | US20130040987 Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders |
| 02/14/2013 | US20130040986 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| 02/14/2013 | US20130040985 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 02/14/2013 | US20130040984 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS |
| 02/14/2013 | US20130040983 Raf kinase inhibitors |
| 02/14/2013 | US20130040982 Oral sustained release formulation of huperzine a |
| 02/14/2013 | US20130040981 Pyridylvinylpyrazoloquinolines as PAR1 inhibitors |
| 02/14/2013 | US20130040980 Cci-779 concentrate formulations |
| 02/14/2013 | US20130040979 Ccr1 inhibitors useful for the treament of multiple myeloma and other disorders |
| 02/14/2013 | US20130040978 Spiro isoxazoline compounds as sstr5 antagonists |
| 02/14/2013 | US20130040977 Pro-Neurogenic Compounds |
| 02/14/2013 | US20130040976 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| 02/14/2013 | US20130040975 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/14/2013 | US20130040974 Piperidine inhibitors of janus kinase 3 |
| 02/14/2013 | US20130040973 JAK PI3K/mTOR COMBINATION THERAPY |
| 02/14/2013 | US20130040972 USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA |
| 02/14/2013 | US20130040971 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| 02/14/2013 | US20130040970 Co-Crystals Of A Triazolo [4,5-D] Pyrimide Platelet Aggregation Inhibitor |
| 02/14/2013 | US20130040968 Fat or oil composition |
| 02/14/2013 | US20130040967 4'-demethylepipodophyllotoxin derivative, preparation method and use thereof |
| 02/14/2013 | US20130040966 Pharmaceutical formulations containing dopamine receptor ligands |
| 02/14/2013 | US20130040965 Aminotetralin compounds as mu opioid receptor antagonists |
| 02/14/2013 | US20130040964 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors |
| 02/14/2013 | US20130040963 Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels |
| 02/14/2013 | US20130040962 P38 MAP Kinase Inhibitors |
| 02/14/2013 | US20130040961 Oligomer modified diaromatic substituted compounds |
| 02/14/2013 | US20130040960 Ophthalmic gel of gatifloxacin and preparation method thereof |
| 02/14/2013 | US20130040959 Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators |
| 02/14/2013 | US20130040958 Imatinib mesylate preparation procedure |
| 02/14/2013 | US20130040957 Deuterium-Enriched Pyrimidine Compounds and Derivatives |
| 02/14/2013 | US20130040956 Process for the preparation of stable, crystalline (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid |
| 02/14/2013 | US20130040955 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| 02/14/2013 | US20130040954 Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| 02/14/2013 | US20130040953 Promotion of wound healing |
| 02/14/2013 | US20130040952 Influenza virus inhibitors that disrupt nucleoprotein trimerization |
| 02/14/2013 | US20130040951 Prophylactic or therapeutic agent for cancer |
| 02/14/2013 | US20130040950 Multisubstituted aromatic compounds as inhibitors of thrombin |
| 02/14/2013 | US20130040949 Type ii raf kinase inhibitors |
| 02/14/2013 | US20130040948 Novel benzodioxole piperazine compounds |
| 02/14/2013 | US20130040947 Trkb agonists and methods of use |
| 02/14/2013 | US20130040946 Substituted imidazopyrimidines and triazolopyrimidines |
| 02/14/2013 | US20130040945 Certain chemical entities, compositions, and methods |
| 02/14/2013 | US20130040944 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| 02/14/2013 | US20130040943 Tricyclic pyridyl-vinyl pyrroles as par1 inhibitors |
| 02/14/2013 | US20130040942 Salts of potassium atp channel openers and uses thereof |
| 02/14/2013 | US20130040941 Benzodiazepine compound and pharmaceutical composition |
| 02/14/2013 | US20130040940 Mercaptoamidine derivatives and methods of use |
| 02/14/2013 | US20130040939 Oral Suspension Formulations of Esclicarbazepine Acetate |
| 02/14/2013 | US20130040938 Compositiions for treating cognitive disorders |
| 02/14/2013 | US20130040937 Inhibitors for treating and preventing heart failure in felines |
| 02/14/2013 | US20130040936 1,4-oxazepines as bace1 and/or bace2 inhibitors |
| 02/14/2013 | US20130040935 Cyclic keto-enols for therapy |
| 02/14/2013 | US20130040934 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 02/14/2013 | US20130040933 Azaindoles as janus kinase inhibitors |
| 02/14/2013 | US20130040932 Substituted aryl sulfone derivatives as calcium channel blockers |
| 02/14/2013 | US20130040931 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use |
| 02/14/2013 | US20130040930 Novel amide derivative and use thereof as medicine |
| 02/14/2013 | US20130040929 Novel prolylcarboxypeptidase inhibitors |
| 02/14/2013 | US20130040928 Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics |
| 02/14/2013 | US20130040927 Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| 02/14/2013 | US20130040926 Novel compound |
| 02/14/2013 | US20130040925 Osmium (ii) arene azo anti-cancer complexes |
| 02/14/2013 | US20130040924 Bridged polycyclic compound based compositions for the inhibition and amelioration of disease |
| 02/14/2013 | US20130040923 Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| 02/14/2013 | US20130040922 Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| 02/14/2013 | US20130040921 Anticancer steroidal lactones unsaturated in position 7 (8) |
| 02/14/2013 | US20130040920 Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and/or pharmaceutical product, and method for enhancing the potential of resveratrol |
| 02/14/2013 | US20130040919 C-nitroso-derived nitroxyl donors |
| 02/14/2013 | US20130040918 Tetracycline compositions |
| 02/14/2013 | US20130040917 Phenazopyridine Compounds |
| 02/14/2013 | US20130040916 Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses |
| 02/14/2013 | US20130040915 Pharmaceutical composition |
| 02/14/2013 | US20130040914 Prodrugs of an hiv reverse transcriptase inhibitor |
| 02/14/2013 | US20130040913 Omega 3 fatty acidfor use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels |
| 02/14/2013 | US20130040912 Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders |
| 02/14/2013 | US20130040911 Adhesion-preventing material |
| 02/14/2013 | US20130040910 Method of treating vitamin b12 deficiency |
| 02/14/2013 | US20130040909 Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| 02/14/2013 | US20130040908 Substitution derivatives of n6-benzyladenosine-5' -monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds |
| 02/14/2013 | US20130040907 Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels |
| 02/14/2013 | US20130040906 Inhibitors of Human EZH2, and Methods of Use Thereof |
| 02/14/2013 | US20130040905 Combination Of Drugs With Protein-Binding Prodrugs |
| 02/14/2013 | US20130040904 Method of treatment using alpha-1-adrenergic agonist compounds |
| 02/14/2013 | US20130040903 Pharmaceutical compositions for treating depression and anxiety |
| 02/14/2013 | US20130040902 Method for enhancing milk quantity and quality |
| 02/14/2013 | US20130040899 Use of PEDF-Derived Polypeptides for Treating Liver Cirrhosis |
| 02/14/2013 | US20130040894 Inhibition or activation of serine/threonine ulk3 kinase activity |
| 02/14/2013 | US20130040879 Methods For Treating Congestive Heart Failure |